This time around the M&A moves will be much bigger in scope, promising to reconfigure the complex and fragile healthcare payer/provider/patient ecosystem.
Gilead may be forced to discount hep. C pills
December 23, 2014
8:17 pm
AbbVie’s deal with the PBM Express Scripts has altered the dynamic in hepatitis C price-setting, writes Bloomberg.
Five things for pharma marketers to know: Monday, December 22
UK drug-cost watchdog backs Sovaldi, Achillion touts HCV interim results, Avastin’s latest cancer indication, Ebola outbreak worsens, COPD drug gets panel nod, and study links quick reviews and black-box warnings.
Employers like “skinny” health plans
August 14, 2014
5:21 pm
These healthcare plans allow employees and employers to avoid ACA penalties but provide little coverage.
Boehringer to cut costs by 15%
August 12, 2014
4:12 pm
Layoffs are reported to be in the offing.
Scotland’s NICE dislikes GSK’s Anoro
August 11, 2014
5:54 pm
The Scottish Medicines Consortium gave a thumb’s down to GSK’s drug and a Boehringer COPD drug.
Britain’s National Institute for Health and Care Excellence has followed through on its Kadcyla objections and has said Roche’s breast cancer drug will remain off the National Health Services formulary because it is too expensive.
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix